Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York
- PMID: 32348641
- PMCID: PMC7204427
- DOI: 10.1056/NEJMc2009567
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York
Comment in
-
How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology.Immunotherapy. 2020 Oct;12(15):1115-1119. doi: 10.2217/imt-2020-0153. Epub 2020 Jul 9. Immunotherapy. 2020. PMID: 32640861 Free PMC article. No abstract available.
-
More on Covid-19 in Immune-Mediated Inflammatory Diseases.N Engl J Med. 2020 Aug 20;383(8):795-796. doi: 10.1056/NEJMc2018011. Epub 2020 Jul 10. N Engl J Med. 2020. PMID: 32649068 No abstract available.
-
More on Covid-19 in Immune-Mediated Inflammatory Diseases.N Engl J Med. 2020 Aug 20;383(8):796. doi: 10.1056/NEJMc2018011. Epub 2020 Jul 10. N Engl J Med. 2020. PMID: 32649069 No abstract available.
-
More on Covid-19 in Immune-Mediated Inflammatory Diseases.N Engl J Med. 2020 Aug 20;383(8):796-797. doi: 10.1056/NEJMc2018011. Epub 2020 Jul 10. N Engl J Med. 2020. PMID: 32649070 No abstract available.
References
-
- ClinicalTrials.gov. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19. 2020. (https://clinicaltrials.gov/ct2/show/NCT04315298).
-
- NYC Department of Health and Mental Hygiene. COVID-19: data. 2020. (https://www1.nyc.gov/site/doh/covid/covid-19-data.page).
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical